Safety and Efficacy of Oral TXA in Reducing Blood Loss and Transfusion in Hip Fractures

Summary

The primary objective of this study is to assess the safety and efficacy of Tranexamic acid (TXA) in reducing blood loss and transfusion requirements for patients with osteoporotic hip fractures. In addition to assessing blood loss in these patients, complications associated with TXA use would be characterized including systemic (pulmonary embolism, deep venous thrombosis, myocardial infarction, stroke) and surgical site (hematoma, infection) events, need for re-hospitalization or re-operation and 30 day mortality.

Timeline

Start

2017-09-18

Primary completion

2017-11-14

Completion

2017-12-15

Outcome

Outcome not reported

Stopped (Enrollment): “Study was terminated due to inability to recruit and collect follow up outcome data.”

Drugs

Indications